MYCN and neuroblastoma: For these experiments, we used the FDA-approved MEK inhibitor trametinib to treat primary neuroblastoma tumors that were growing in 3-week-old nf1a-/-;nf1b+/+;MYCN; EGFP fish (Figure 8).